#

Biotechnology

: 100
Sarepta plunges 40% after-hours as muscle disease drugs fail confirmatory trial
Small Caps·
Sarepta plunges 40% after-hours as muscle disease drugs fail confirmatory trial
OpenAIs $1 trillion listing and a rebound in the UK market: highlights of IPOs by Nov. 2
News·
OpenAI's $1 trillion listing and a rebound in the UK market: highlights of IPOs by Nov. 2
Canaccord initiates on obesity drugmaker Viking with buy, sees 200% upside
Small Caps·
Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside
Novartis $12 bln deal for Avidity sparks mid-cap biotech rally
Small Caps·
Novartis $12 bln deal for Avidity sparks mid-cap biotech rally
Freedom Broker names biggest small cap outperformer and underperformer from last week
Small Caps·
Freedom Broker names biggest small cap outperformer and underperformer from last week
Novo-backed schizophrenia drugmaker MapLight Therapeutics debuts on Nasdaq
News·
+1
·
Novo-backed schizophrenia drugmaker MapLight Therapeutics debuts on Nasdaq
Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data
Small Caps·
Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data
Minerva soars 140% on up to $200 mln raise to finish schizophrenia drug trial
Small Caps·
Minerva soars 140% on up to $200 mln raise to finish schizophrenia drug trial
Noble initiates on ALS drugmaker NeuroSense with outperform, TP for 600% upside
Small Caps·
Noble initiates on ALS drugmaker NeuroSense with 'outperform', TP for 600% upside
Biotech Rani rockets 250% in a day on Chugai collaboration, private placement
Small Caps·
Biotech Rani rockets 250% in a day on Chugai collaboration, private placement
Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell
News·
Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell
After lead drug misses in late trial and stock craters, whats next for aTyr?
Small Caps·
After lead drug misses in late trial and stock craters, what's next for aTyr?
Load more